ArticleNeuro-oncology advances
Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitogen activating protein kinase kinase inhibitors (MEKi) provide clinical benefit to patients with symptomatic, inoperable plexiform neurofibromas (PNs) in Neurofibromatosis type 1 (NF1). Several cases of MPNST developing in patients while receiving MEKi for PN have been reported, raising the question whether MEKi therapy might increase this risk. We report the incidence of MPNST in those who have received MEKi, non-MEKi (eg, mTOR inhibitors), and no PN-directed medical therapies and assess the risk of MPNST in patients who received MEKi. Methods: Patients evaluated at the National Cancer Institute (NCI) with a clinical or genetic diagnosis of NF1 from 1/1/1998 to 12/31/2019 were included in this analysis ( Results: No difference in MPNST risk (HR: 1.09, 95% CI: 0.30-4.01) between MEKi as compared to non-MEKi treatment was observed after adjusting for radiation exposure. Radiation exposure was associated with a higher risk of MPNST (HR: 5.15, 95% CI: 1.15-23.04). Other patient characteristics, including NF1 inheritance pattern, were not associated with the risk of MPNST development in this cohort. Conclusion: Our data do not demonstrate a significant difference in the risk of MPNST development between patients with NF1-PN who received MEKi and non-MEKi treatments. Radiation exposure was significantly associated with a higher risk of MPNST development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.